The Thrombocytopenia drugs in development market research report provides comprehensive information on the therapeutics under development for Thrombocytopenia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Thrombocytopenia. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights Thrombocytopenia - Drugs In Development, 2023

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Thrombocytopenia and features dormant and discontinued products.

GlobalData tracks 87 drugs in development for Thrombocytopenia by 86 companies/universities/institutes. The top development phase for Thrombocytopenia is preclinical with 26 drugs in that stage. The Thrombocytopenia pipeline has 81 drugs in development by companies and six by universities/ institutes. Some of the companies in the Thrombocytopenia pipeline products market are: Takeda Pharmaceutical, Novartis and GC Biopharma.

The key targets in the Thrombocytopenia pipeline products market include Thrombopoietin Receptor (Myeloproliferative Leukemia Protein or Proto Oncogene c Mpl or CD110 or MPL), Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2), and Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2).

The key mechanisms of action in the Thrombocytopenia pipeline product include Thrombopoietin Receptor (Myeloproliferative Leukemia Protein or Proto Oncogene c Mpl or CD110 or MPL) Agonist with 16 drugs in Pre-Registration. The Thrombocytopenia pipeline products include four routes of administration with the top ROA being Intravenous and 19 key molecule types in the Thrombocytopenia pipeline products market including Small Molecule, and Monoclonal Antibody.

Thrombocytopenia overview

Thrombocytopenia refers to a lower than normal platelet count in the blood. Platelets are crucial for blood clotting and preventing bleeding. Various factors can cause thrombocytopenia, including certain medications, infections, autoimmune disorders, or conditions affecting bone marrow function. Symptoms may range from mild bruising and petechiae (small red or purple spots on the skin) to more severe bleeding in the nose, gums, or internally. Treatment depends on the underlying cause and severity, often involving medication adjustments, platelet transfusions, or addressing the primary condition. Monitoring platelet counts and managing potential bleeding risks are essential in managing thrombocytopenia.

For a complete picture of Thrombocytopenia’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.